The estimated Net Worth of Christopher J Lindop is at least 27.5 百万$ dollars as of 24 May 2020. Christopher Lindop owns over 25,271 units of Haemonetics stock worth over 27,288,075$ and over the last 18 years Christopher sold HAE stock worth over 182,274$.
Christopher has made over 31 trades of the Haemonetics stock since 2007, according to the Form 4 filled with the SEC. Most recently Christopher exercised 25,271 units of HAE stock worth 1,830,884$ on 24 May 2020.
The largest trade Christopher's ever made was exercising 68,628 units of Haemonetics stock on 18 June 2013 worth over 1,806,289$. On average, Christopher trades about 5,673 units every 72 days since 2007. As of 24 May 2020 Christopher still owns at least 376,647 units of Haemonetics stock.
You can see the complete history of Christopher Lindop stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O QUOTIENT LIMITED, 28 ESPLANADE, ST HELIER, Y9, JE2 3QA.
Over the last 21 years, insiders at Haemonetics have traded over 82,114,016$ worth of Haemonetics stock and bought 334,931 units worth 14,646,550$ . The most active insiders traders include Paul Black、Robert E Abernathy、Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of 539,753$. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth 393,039$.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: